Genomic Testing Co. Preps $100M IPO Led By Cooley, Latham
Decipher Biosciences, a genomic testing company focused on prostate and bladder cancer, filed for a $100 million initial public offering Tuesday with guidance from Cooley LLP and Latham & Watkins LLP....To view the full article, register now.
Already a subscriber? Click here to view full article